Get App
Download App Scanner
Scan to Download
Advertisement

Dixon Tech To V-Guard Q4 Results Review — Check Target Prices, Potential Upside, Ratings, Stock Calls By HDFC Securities

Brokerage firm HDFC Securities has shared its Q4 review across key companies, highlighting a mixed earnings performance. While companies like Syrma and Berger Paints delivered strong growth, others including Dr. Reddy's and Dixon faced pressure on margins and demand outlook.

Dixon Tech To V-Guard Q4 Results Review — Check Target Prices, Potential Upside, Ratings, Stock Calls By HDFC Securities
HDFC Securities, in its latest Q4 results review, has shared a mixed outlook across a wide set of stocks, with clear stock-specific calls spanning Buy, Add and Reduce ratings along with revised target prices.
(Photo: NDTV Profit)
STOCKS IN THIS STORY
Dixon Technologies (India) Ltd.
--
Canara Bank
--
Syrma SGS Technology Ltd.
--
Stylam Industries Ltd.
--
Dr. Reddys Laboratories Ltd.
--
V-Guard Industries Ltd.
--
Berger Paints India Ltd.
--

NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.

HDFC Securities Institutional Equities

HDFC Securities, in its latest Q4 FY26 results review, has shared a mixed outlook across a wide set of stocks including Canara Bank, Dr. Reddy's, Dixon, Berger Paints, Syrma, V-Guard, Stylam with clear stock-specific calls spanning Buy, Add and Reduce ratings along with revised target prices.

Dixon Technologies Ltd. posted modest revenue growth of 2% YoY, while Ebitda declined due to margin compression. The outlook remains challenging amid PLI incentive withdrawal and slow handset demand. The brokerage has downgraded the stock to Reduce with a target price of Rs 10,560.

Canara Bank reported steady loan growth of around 16% YoY, led by retail and MSME segments. However, earnings were impacted by weak treasury income and reliance on non-core income streams.The brokerage maintains an Add rating with a target price of Rs 155, but flags concerns around deposit franchise strength and earnings volatility.

Dr Reddy's saw Ebitda plunge 42% YoY amid a sales decline and margin contraction, largely due to a sharp drop in US business.  Growth visibility remains tied to Semaglutide launches and biosimilars pipeline, though HDFC Sec retains a Reduce rating with a target price of Rs 1,260.

Click on the attachment to read the full report:

Hdfc Securities Q4 Results Review.pdf
VIEW DOCUMENT

ALSO READ: Berger Paints in Focus as Systematix Retains Buy After Strong Q4 — Check Target Price

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.

To continue reading this story
You must be an existing Premium User

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search
Add NDTV Profit As Google Preferred Source
Loading PDF...